Kinnate Biopharma Inc.
(NASDAQ:KNTE)
$7.32
0.18 (2.52%)
At Close: 4:00 PM
KNTE Financial
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
Quick Ratio
17
Enterprise Value/Revenue
-
Fiscal Year Ends
Dec
Current Ratio
17
Peg Ratio (5 yr Expected)
-
Enterprise Value/EBITDA
-
Most Recent Quarter (MRQ)
Jun. 2022
Next Earning Date
2022-11-10
Profit Margin
-
Revenue (TTM)
-
Quarterly Revenue Growth (YOY)
-
Operating Margin (TTM)
-
Revenue Per Share (TTM)
-
SALES GROWTH PAST 5Y
-
Operating Margin
(TTM)
-
Profit Margin
-
Revenue
(TTM)
-
Revenue Per Share
(TTM)
-
Return & Ratios
It is true that no indicator can be relied on to predict company health 100% of the time. However, a number of indicators can provide insight into trading trends. A number of ratios can measure a company's strength, both in comparison to its peers and to its past performance. A number of ratios can be used to measure the performance of an organization, such as the Return On Investment (ROI), Return On Assets (ROA) as well as Return On Equity (ROE).
Gross Margin
-
Return on Investment (TTM)
-
Return on Equity (TTM)
-39%
Gross Profit (TTM)
-
Return on Assets (TTM)
-33.10%
Net Income AVI To Common (TTM)
0
EBITDA
0
DILUTED EPS (TTM)
-2.52
Quarterly Earnings Growth (YOY)
-23.10%
Graph For Net Income
Graph For EBITDA
Cash & Equity Ratios
Total Cash (MRQ)
262.42 Million
Total Debt (MRQ)
4.54 Million
Book Value Per Share (MRQ)
7.81
Levered Free Cash Flow (TTM)
0
Total Cash Per Share (MRQ)
7.81
Total Debt/Equity (MRQ)
0
Operating Cash Flow (TTM)
0
Total Cash
Total Cash Per Share
Book Value Per Share
Operating Cash Flow
Frequently Asked Questions
When was the last time Kinnate Biopharma Inc. (NASDAQ:KNTE) reported earnings?
Kinnate Biopharma Inc. (KNTE) published its most recent earnings results on Nov. 2022 for the quarter ended Jun. 2022.
What is Kinnate Biopharma Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Kinnate Biopharma Inc. (NASDAQ:KNTE)'s trailing twelve month ROE is -39%.
What are ROA and ROI telling us?
It is sometimes helpful for shareholders to know how their investments are doing. Return on investment (ROI) for Kinnate Biopharma Inc. (KNTE) is N/A. As ROI percentages rise, profits exceed costs, thus analysts consider such investments to be a general win. In contrast, the Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Kinnate Biopharma Inc. (KNTE) currently has a ROA of -33.10% Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did KNTE's net profit margin stand at?
KNTE reported a profit margin of N/A in the last quarter ended Jun. 2022. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
When will Kinnate Biopharma Inc.'s next earnings report be released?
Although Kinnate Biopharma Inc. has not yet announced its next earnings date, it is expected to be, Nov. 10, 2022 based on last year's announcement date.
What is KNTE's short-term liquidity position?
According to Kinnate Biopharma Inc. (KNTE)'s current performance indicators, the Quick Ratio of 17 in the last reported quarter. The current ratio of KNTE stands at 17 in the last reported quarterand a Debt/Eq ratio of 0.